BWX Technologies (NYSE:BWXT) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of BWX Technologies (NYSE:BWXT) in a report released on Monday morning, MarketBeat reports. The firm issued an overweight rating and a $230.00 target price on the technology company’s stock.

Several other analysts have also recently issued reports on BWXT. Weiss Ratings reiterated a “buy (b-)” rating on shares of BWX Technologies in a research report on Friday, May 22nd. Truist Financial boosted their price target on BWX Technologies from $205.00 to $212.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Seaport Research Partners upgraded BWX Technologies from a “neutral” rating to a “buy” rating and set a $245.00 price target for the company in a research note on Monday, June 22nd. Deutsche Bank Aktiengesellschaft raised shares of BWX Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $205.00 to $255.00 in a report on Friday, May 15th. Finally, Wells Fargo & Company initiated coverage on shares of BWX Technologies in a research report on Wednesday, April 1st. They set an “underweight” rating and a $200.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $228.20.

BWX Technologies Trading Up 1.3%

Shares of BWX Technologies stock opened at $176.79 on Monday. The company has a market capitalization of $16.20 billion, a P/E ratio of 47.27, a P/E/G ratio of 2.98 and a beta of 0.74. The company has a debt-to-equity ratio of 1.58, a quick ratio of 2.33 and a current ratio of 2.40. The company has a fifty day moving average of $190.91 and a 200 day moving average of $202.71. BWX Technologies has a fifty-two week low of $143.07 and a fifty-two week high of $241.82.

BWX Technologies (NYSE:BWXT) last issued its quarterly earnings results on Monday, May 4th. The technology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. BWX Technologies had a return on equity of 31.33% and a net margin of 10.20%.The business had revenue of $860.22 million during the quarter, compared to analyst estimates of $837.47 million. During the same quarter in the prior year, the business posted $0.91 EPS. BWX Technologies’s revenue for the quarter was up 26.1% compared to the same quarter last year. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. On average, sell-side analysts anticipate that BWX Technologies will post 4.6 earnings per share for the current fiscal year.

BWX Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 5th. Stockholders of record on Tuesday, May 19th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Tuesday, May 19th. BWX Technologies’s payout ratio is 28.88%.

Insider Transactions at BWX Technologies

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $204.81, for a total transaction of $2,048,100.00. Following the completion of the transaction, the chief executive officer owned 202,491 shares in the company, valued at $41,472,181.71. This trade represents a 4.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Thomas Fitzgerald sold 2,417 shares of BWX Technologies stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $209.25, for a total value of $505,757.25. Following the completion of the sale, the chief financial officer directly owned 6,884 shares in the company, valued at approximately $1,440,477. The trade was a 25.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. WFA of San Diego LLC bought a new stake in BWX Technologies in the second quarter worth $29,000. MV Capital Management Inc. bought a new position in BWX Technologies during the fourth quarter valued at $32,000. Tucker Asset Management LLC purchased a new position in shares of BWX Technologies in the 4th quarter worth $36,000. ORG Partners LLC grew its stake in shares of BWX Technologies by 143.2% in the 4th quarter. ORG Partners LLC now owns 231 shares of the technology company’s stock worth $40,000 after buying an additional 136 shares in the last quarter. Finally, Vermillion Wealth Management Inc. grew its stake in shares of BWX Technologies by 71.7% in the 4th quarter. Vermillion Wealth Management Inc. now owns 237 shares of the technology company’s stock worth $41,000 after buying an additional 99 shares in the last quarter. 94.39% of the stock is currently owned by institutional investors.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.